{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:01:50Z","timestamp":1790762510813,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-023-10304-7","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:22:40Z","timestamp":1679869360000},"page":"1211-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of American and European guidelines for cardio-oncology of heart failure"],"prefix":"10.1007","volume":"28","author":[{"given":"Jun-Zhang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1749-6976","authenticated-orcid":false,"given":"Bo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"17","key":"10304_CR1","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):1757\u20131780","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10304_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"1","key":"10304_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-020-01024-5","volume":"19","author":"B Liang","year":"2020","unstructured":"Liang B, Zhao Y-X, Zhang X-X, Liao H-L, Gu N (2020) Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol 19(1):55","journal-title":"Cardiovasc Diabetol"},{"key":"10304_CR4","doi-asserted-by":"publisher","first-page":"744243","DOI":"10.3389\/fcvm.2021.744243","volume":"8","author":"B Liang","year":"2021","unstructured":"Liang B, Li R, Bai J-Y, Gu N (2021) Bioimpedance vector analysis for heart failure: should we put it on the agenda? Front Cardiovasc Med 8:744243","journal-title":"Front Cardiovasc Med"},{"issue":"10120","key":"10304_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP et al (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391(10120):572\u2013580","journal-title":"Lancet"},{"issue":"1","key":"10304_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH (2017) Global public health burden of heart failure. Card Fail Rev 3(1):7\u201311","journal-title":"Card Fail Rev"},{"issue":"10","key":"10304_CR7","doi-asserted-by":"publisher","first-page":"e2022190","DOI":"10.1001\/jamanetworkopen.2020.22190","volume":"3","author":"R Khera","year":"2020","unstructured":"Khera R, Kondamudi N, Zhong L, Vaduganathan M, Parker J, Das SR et al (2020) Temporal trends in heart failure incidence among medicare beneficiaries across risk factor strata, 2011 to 2016. JAMA Netw Open 3(10):e2022190","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10304_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00392-014-0788-x","volume":"104","author":"S Meyer","year":"2015","unstructured":"Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT et al (2015) Sex differences in new-onset heart failure. Clin Res Cardiol 104(4):342\u2013350","journal-title":"Clin Res Cardiol"},{"issue":"19","key":"10304_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","volume":"34","author":"FP Brouwers","year":"2013","unstructured":"Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ et al (2013) Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 34(19):1424\u20131431","journal-title":"Eur Heart J."},{"issue":"8","key":"10304_CR10","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS et al (2022) Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145(8):e153\u2013e639","journal-title":"Circulation"},{"issue":"7","key":"10304_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ejhf.110","volume":"16","author":"EE van Riet","year":"2014","unstructured":"van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH (2014) Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 16(7):772\u2013777","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10304_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10304_CR13","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.jacc.2015.04.059","volume":"65","author":"A Barac","year":"2015","unstructured":"Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J et al (2015) Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 65(25):2739\u20132746","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10304_CR14","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","volume":"40","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, Suter TM, L\u00f3pez-Fern\u00e1ndez T, Galderisi M, Lyon AR, Van der Meer P et al (2019) Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40(22):1756\u20131763","journal-title":"Eur Heart J"},{"issue":"41","key":"10304_CR15","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"issue":"7","key":"10304_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.1758","volume":"22","author":"J Tromp","year":"2020","unstructured":"Tromp J, Boerman LM, Sama IE, Maass S, Maduro JH, Hummel YM et al (2020) Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail 22(7):1239\u20131246","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10304_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ejhf.1620","volume":"22","author":"NB Boekel","year":"2020","unstructured":"Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS et al (2020) Heart failure after treatment for breast cancer. Eur J Heart Fail 22(2):366\u2013374","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10304_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","volume":"20","author":"P Ameri","year":"2018","unstructured":"Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A et al (2018) Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 20(5):879\u2013887","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10304_CR19","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945\u20131960","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10304_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ejhf.1385","volume":"21","author":"K Keramida","year":"2019","unstructured":"Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA et al (2019) Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail 21(4):529\u2013535","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10304_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 22(9):1504\u20131524","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10304_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J et al (2021) Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 77(4):392\u2013401","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10304_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T et al (2020) Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 22(2):350\u2013361","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10304_CR24","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, Henriksen PA, Lenihan D, Dent S et al (2020) Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22(11):1966\u20131983","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10304_CR25","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/ejhf.1168","volume":"20","author":"A Banke","year":"2018","unstructured":"Banke A, Fosb\u00f8l EL, M\u00f8ller JE, Gislason GH, Andersen M, Bernsdorf M et al (2018) Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail 20(10):1447\u20131453","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10304_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-019-05178-z","volume":"176","author":"MM Abu-Khalaf","year":"2019","unstructured":"Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E et al (2019) Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat 176(2):261\u2013270","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10304_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-018-05114-7","volume":"174","author":"P O'Brien","year":"2019","unstructured":"O\u2019Brien P, Matheson K, Jeyakumar A, Anderson K, Younis T (2019) The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 174(2):357\u2013363","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10304_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","volume":"11","author":"ML Henry","year":"2018","unstructured":"Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M (2018) Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 11(8):1084\u20131093","journal-title":"JACC Cardiovasc Imaging"},{"issue":"23","key":"10304_CR29","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474\u20132481","journal-title":"Circulation"},{"key":"10304_CR30","doi-asserted-by":"crossref","unstructured":"Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I et al (2022) Cardioprotective strategies from cardiotoxicity in cancer patients: a comprehensive review. J Cardiovasc Dev Dis 9(8)","DOI":"10.3390\/jcdd9080259"},{"issue":"2","key":"10304_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J (2017) Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol 17(2):130\u2013139","journal-title":"Cardiovasc Toxicol"},{"issue":"5","key":"10304_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","volume":"69","author":"M Nabati","year":"2017","unstructured":"Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69(5):279\u2013285","journal-title":"J Cardiovasc Pharmacol"},{"issue":"23","key":"10304_CR33","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61(23):2355\u20132362","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10304_CR34","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680","journal-title":"Eur Heart J"},{"issue":"3","key":"10304_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","volume":"24","author":"S Huang","year":"2019","unstructured":"Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K et al (2019) Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev 24(3):325\u2013333","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10304_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","volume":"1","author":"M Vaduganathan","year":"2019","unstructured":"Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V et al (2019) Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol 1(1):54\u201365","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10304_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L et al (2019) Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol 1(1):68\u201379","journal-title":"JACC CardioOncol"},{"key":"10304_CR38","doi-asserted-by":"publisher","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","volume":"151","author":"X Li","year":"2020","unstructured":"Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B et al (2020) Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res 151:104577","journal-title":"Pharmacol Res"},{"issue":"2","key":"10304_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","volume":"16","author":"F Caspani","year":"2021","unstructured":"Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A (2021) Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Intern Emerg Med 16(2):477\u2013486","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10304_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","volume":"26","author":"K Fang","year":"2021","unstructured":"Fang K, Zhang Y, Liu W, He C (2021) Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. Heart Fail Rev 26(1):101\u2013109","journal-title":"Heart Fail Rev"},{"issue":"22","key":"10304_CR41","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","volume":"40","author":"P Ferdinandy","year":"2019","unstructured":"Ferdinandy P, Baczk\u00f3 I, Bencsik P, Giricz Z, G\u00f6rbe A, Pacher P et al (2019) Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 40(22):1771\u20131777","journal-title":"Eur Heart J"},{"issue":"36","key":"10304_CR42","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768\u20132801","journal-title":"Eur Heart J"},{"issue":"13","key":"10304_CR43","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49(13):2900\u20132909","journal-title":"Eur J Cancer"},{"issue":"2","key":"10304_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171\u2013190","journal-title":"Ann Oncol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10304-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T20:28:58Z","timestamp":1691180938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10304-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["10304"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10304-7","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"1 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}